| | Current Science News - Endo Announces Positive Results From Its Extended-Release Oxymorphone Study (Site not responding. Last check: 2007-10-09) |
 | | Of the patients in the intent-to-treat analysis population, the incidence of adverse events for oxymorphone ER versus placebo was as follows: nausea (11.4% vs. 9%), vomiting (7.6% vs. 1%), constipation (6.7% vs. 1%) and opioid-related CNS effects (11.4% vs. 6%). |
 | | Oxymorphone is a semi-synthetic u-opioid agonist that has been formulated as a 12-hour extended-release (ER) tablet using Penwest Pharmaceuticals' proprietary time-release technology TIMERx(R) delivery system. |
 | | Oxymorphone ER has been studied in a wide range of chronic pain conditions, including low back pain, osteoarthritis pain, post-surgical pain and cancer pain. |
| www.lifesciencesworld.com /news/news-6023.htm (847 words) |